The proliferation rate paradox in antimitotic chemotherapy.
about
Kinesin-5: cross-bridging mechanism to targeted clinical therapyCancer metabolism and oxidative stress: Insights into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of methotrexateAntimitotic drugs in the treatment of cancerTargeting the Mitotic Catastrophe Signaling Pathway in CancerHitting the brakes: targeting microtubule motors in cancerA critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapyNuclear assembly as a target for anti-cancer therapiesCell-to-cell variability in cell death: can systems biology help us make sense of it all?Intravital FRET imaging of tumor cell viability and mitosis during chemotherapyGTSE1 is a microtubule plus-end tracking protein that regulates EB1-dependent cell migrationPrevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agentsNecrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptionsThe NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrestLongitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor.A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.How Taxol/paclitaxel kills cancer cells.Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer.Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyMetrics other than potency reveal systematic variation in responses to cancer drugs.Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.FLIM-FRET for Cancer Applications.Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the Kinesin-5 inhibitor monastrol.A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1.Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanesMYC Is a Major Determinant of Mitotic Cell Fate.Iberis amara Extract Induces Intracellular Formation of Reactive Oxygen Species and Inhibits Colon CancerIPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma.In vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy.Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesisMicrotubule drugs: action, selectivity, and resistance across the kingdoms of life.Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.Piperlongumine and immune cytokine TRAIL synergize to promote tumor deathAn expanding role for cell biologists in drug discovery and pharmacology.Cancer cell-selective killing polymer/copper combination.Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma.Eribulin targets a ch-TOG-dependent directed migration of cancer cellsBreast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time.Cellular uptake and anticancer activity of carboxylated gallium corroles
P2860
Q21710690-7DE93169-ABE8-4C9C-9C64-5B6177EE603CQ26775475-36DEAD74-E719-410C-AABC-3F3F7766FC67Q26777317-61D100C9-B178-4606-8761-0BB63D5EF950Q26778544-BD28B948-DEA3-4E1A-A00B-47DBF66E3FC3Q26800271-43395D82-6BB1-4B26-B3FC-DB4FE17F6B3AQ26849503-A3E83A96-124B-4404-A861-AD0216B462CDQ26852806-55CCD8C7-283E-466A-8B00-533EBA73BFD7Q27013063-96CAEE36-3F72-42DD-BE2D-B1AEF23EF59FQ27319918-F812A185-D6F0-4B62-A1BD-238009FD6EF6Q27331882-6ACBD864-7DDC-4DA1-B674-DFF07993DA23Q28240178-920721E8-7DDE-49D2-AE15-68EEFDC66794Q28652643-B4D13B97-8C3E-42BE-BDEE-CB5D067E0E83Q30648719-CF0EDE5C-DA30-484A-9083-220206F9E333Q30665952-AEAF89B5-3F14-40B8-B738-5E0C7F7C9CB5Q33689457-75A443F5-CC07-47BF-A93D-375F941FDC6EQ34166802-09241603-D53E-4DAE-8025-A7E9860D0BD3Q34365904-E3A4C313-9814-48DA-8265-6EF759C3F512Q34567461-FCA85DF2-AAB6-4C96-A932-4CC6A279D70EQ34980827-CEF2B3A0-2C5D-461C-8AF6-783548198D7CQ35021459-92334E9E-B784-494B-9007-8A0C5A09C030Q35062586-7ED08C4D-ADF3-4098-998E-532FF85F84C0Q35646933-59903278-6597-40DE-8A7F-B13899E78CE1Q35649837-B695FD50-25B5-4DEC-A900-12D32E55435EQ35677134-0B75B1D8-0561-42FF-BC18-0122DAC584C2Q35809557-9F59ED43-B176-40EC-8FAE-8791697D1D59Q35856517-E4D59F6E-495E-496A-91BA-B0E33D0D3657Q35898987-4CF66A84-BFE1-4612-84C8-C98BD6EC54D2Q35981239-102502B0-8964-4922-8DDB-65ADB072B8B5Q35987440-D9AA4738-042E-4ABB-9F50-11B33DFE1DA8Q36084123-AB218449-47D4-43B8-B48F-CD76F320D73BQ36200232-62401849-FEB1-4D7E-B170-D7D9FE76D37CQ36203343-BAB0CD1D-455B-4C26-8AD5-31855B82200FQ36214686-6D15A1CF-9A34-4C45-9A4B-2248D8784167Q36292383-A9AF56EC-1E25-4A77-9C38-E55D39583A9CQ36356498-48150CCF-8E8A-4174-AEBA-33C5A74AF3F9Q36372931-DF083F3D-1FCE-45AF-BE60-1301E7942058Q36424035-9408BCD1-CB3A-4924-B482-821E3DA610F8Q36561555-78527961-AD91-4DEB-B0FD-95C7AD445E02Q36742357-09147AAD-9897-4B2C-B7DE-7B85D8EBDADBQ36831581-33964A41-134A-4A71-A394-5747C7B40351
P2860
The proliferation rate paradox in antimitotic chemotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The proliferation rate paradox in antimitotic chemotherapy.
@ast
The proliferation rate paradox in antimitotic chemotherapy.
@en
type
label
The proliferation rate paradox in antimitotic chemotherapy.
@ast
The proliferation rate paradox in antimitotic chemotherapy.
@en
prefLabel
The proliferation rate paradox in antimitotic chemotherapy.
@ast
The proliferation rate paradox in antimitotic chemotherapy.
@en
P2860
P356
P1476
The proliferation rate paradox in antimitotic chemotherapy.
@en
P2093
Timothy J Mitchison
P2860
P356
10.1091/MBC.E10-04-0335
P577
2012-01-01T00:00:00Z